Lexaria Awarded New Patents
- None.
- None.
The recent patent awards for Lexaria Bioscience Corp. in the fields of epilepsy and anti-viral agents represent a strategic enhancement of the company's intellectual property portfolio. Patents are a critical asset for pharmaceutical companies, providing exclusive rights that can prevent competitors from entering the market with similar products. The addition of these patents can potentially create barriers to entry for competitors, giving Lexaria a competitive edge.
Furthermore, the patents for DehydraTECH-CBD, which has shown effectiveness in mitigating epileptic seizures and improved absorption over existing treatments, could signal a significant advancement in epilepsy treatment options. This is particularly relevant as the patents cover both swallowed capsules and dissolvable oral tablets, which could cater to patient preferences and improve compliance.
The patent in Japan for enhanced delivery of antiviral agents further diversifies the company's patent portfolio geographically, which is important for protecting market share in different regions. Given that Japan is one of the largest pharmaceutical markets in the world, this could lead to fruitful business opportunities for Lexaria in Asia.
Overall, these patents could enhance Lexaria's valuation and attractiveness to investors, as the company now has a more robust defense against competition and a clear path to potentially capitalize on its research and development efforts.
Lexaria's expansion of its patent portfolio to 41 granted patents worldwide is a testament to the company's commitment to innovation and its potential for growth within the biotech industry. The focus on drug delivery platforms, as evidenced by the DehydraTECH technology, is particularly noteworthy. Drug delivery systems are essential for improving the efficacy and safety of pharmaceutical compounds and innovations in this area can be highly disruptive.
The specific mention of DehydraTECH's effectiveness compared to Epidiolex®, a cannabinoid-based anti-seizure medication, highlights the competitive landscape in the epilepsy treatment market. If Lexaria's technology proves to be superior in human trials, it could significantly impact the current standard of care and influence the prescribing habits of healthcare professionals.
In the long term, the success of these patents relies on the ability to translate these early findings into clinically relevant outcomes and ultimately, marketable products. The company's future business objectives will likely revolve around forming strategic partnerships, securing regulatory approvals and scaling up production to meet potential market demand.
The issuance of patents for compositions and methods for treating epilepsy and enhancing the delivery of antiviral agents is indicative of the progress in medical research and development at Lexaria. The company's focus on improving the bioavailability and effectiveness of drugs through its DehydraTECH technology is of particular interest to the medical community. Increased bioavailability means that a lower dose of the active ingredient might be required to achieve the desired therapeutic effect, potentially reducing side effects and improving patient outcomes.
The granted patents also suggest that Lexaria is making headway in the preclinical stage, a critical phase in drug development. The reference to animal studies showing improved delivery of antiviral drugs by 42% to 204% is significant, as it may lead to more effective treatments for viral diseases, which is a substantial public health concern.
As patents are a key indicator of a company's research trajectory, the extension of Lexaria's patent portfolio until 2041 and 2042 could provide long-term stability and confidence for stakeholders. However, the true impact on the business and the stock market will depend on the subsequent clinical trial outcomes and the ability to bring these innovations to market.
Lexaria receives new patents in the fields of epilepsy and anti-viral agents
KELOWNA, BC / ACCESSWIRE / April 2, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three recent patent awards.
The Company has recently received two new granted patents in Lexaria's patent family #24, Compositions and Methods for Treating Epilepsy, both awarded in the USA. These patents complement earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication, Epidiolex®. Each of these patents will expire in 2042 if not extended. These are the first patents awarded to Lexaria within this important patent family, where there are also international applications currently being processed, and they cover both swallowed capsules and dissolvable oral tablets.
The Company has received a granted patent in Japan in Lexaria's patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. Lexaria previously established in animal studies, that DehydraTECH processing of several antiviral drugs resulted in delivery improvements of between
With the issuance of these new patents, Lexaria is now managing a patent portfolio of 41 granted patents worldwide. Lexaria's intellectual property remains a significant component in supporting future business objectives.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on accesswire.com
